Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Gastroenterology,Hepatology
Reference20 articles.
1. The current and future disease burden of chronic hepatitis C virus infection in Egypt;Waked;Arab J Gastroenterol,2014
2. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients;Planas;J Hepatol,2004
3. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective solar 2 trial;Manns;J Hepatol,2015
4. Boceprevir in addition to standard of care enhanced svr in hepatitis c virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of sprint-2 and respond-2 studies;Bruno;J Hepatol,2011
5. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3;Foster;J Hepatol,2015
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C;Clinical and Experimental Medicine;2024-08-08
2. Chlorogenic acid from sunflower meal regulates the number of immunocompetent cells in animals with toxic liver fibrosis;Clinical Nutrition Open Science;2024-02
3. Effectiveness of second-generation direct-acting antivirals in patients infected with hepatitis c virus and factors associated with a nonsustained virological response;Brazilian Journal of Pharmaceutical Sciences;2024
4. A multicentric and nationwide predictive study role of T cell sub‐population in the prevalence and prognosis of cryoglobulinemia among genotype 4 chronic hepatitis C patients;Journal of Medical Virology;2023-12
5. Outcomes of direct-acting antivirals in patients with HCV decompensated cirrhosis: a systematic review and meta-analysis;Frontiers in Medicine;2023-11-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3